Skip to content

Maze Therapeutics

US · MAZE #2998 by market cap Listed 2025
31.37 -1.06 -3.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 31.80 -1.94%
After-hours 31.37 0.00%
36.7322.3931.372026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MAZE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -1.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 12.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Operating margin 34.4% Better than 92%
Net margin 2.0% Better than 33%
Return on equity -599.0% Better than 1%
Return on invested capital -305.0% Better than 0%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 6.6% Better than 86%
6-month return 21.7% Better than 84%
12-month return (ex latest month) -14.5% Better than 19%
Distance below 52-week high 41.5% Better than 27%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 15.5x Better than 97%
Debt to assets 5.9% Better than 78%
Free cash flow / net income 143.2% Better than 63%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 96.9% Better than 83%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.62%
1M -3.33%
3M +8.43%
6M +25.33%
YTD -24.28%
1Y -11.81%

Key statistics

Price & volume

Prev close
32.43
Open
31.77
Day range
30.88 - 32.80
Avg price
31.67
Volume
818.93K
Turnover
25.94M
Amplitude
5.92%
52-week range
21.95 - 53.65

Valuation

P/E
-11.80
P/E (TTM)
-11.69
P/B
4.00
EPS
-2.66
Net profit
-145.35M
Net assets
428.55M

Share structure

Market cap
1.72B
Float cap
1.17B
Shares out
54.68M
Float shares
37.25M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2025-01-31
52-week range 30% of range
21.95 53.65

41.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.86M net over the window

Short interest

Shares short
6.68M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Maze Therapeutics (MAZE)?

Maze Therapeutics last traded at 31.37. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Maze Therapeutics's market cap?

About 1.72B.

What is the P/E ratio of Maze Therapeutics?

The trailing twelve-month P/E is -11.69, below its own 5-year average of 20.42 — in the middle of its historical range (43.61% percentile). See the Valuation tab for the full history.

Does Maze Therapeutics pay a dividend?

Maze Therapeutics does not currently pay a regular dividend.

Is Maze Therapeutics a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 61.78, which implies 96.9% upside from the current price. This is not investment advice.

What is Maze Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Maze Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Maze Therapeutics discussion 0 comments

Add a comment